Literature DB >> 28616579

Common genetic variation in the germline influences where and how tumors develop.

Hannah Carter1,2,3,4, Trey Ideker1,2,3,4,5.   

Abstract

Germline variation contributes to individual risk for developing specific types of cancer. Analyzing thousands of tumors, we found evidence that the germline also influences vulnerable tissue sites and the mutations that arise in tumor genomes. These associations provide new clues to unravel the biologic mechanisms underlying cancer predisposition.

Entities:  

Keywords:  Cancer predisposition; germline-somatic interactions; tumor evolution

Year:  2017        PMID： 28616579      PMCID： PMC5462515          DOI： 10.1080/23723556.2017.1302905

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Somatic and germline genetics at the JAK2 locus.

Authors:  Peter J Campbell
Journal:  Nat Genet       Date:  2009-04       Impact factor: 38.330

2.  A systematic review of cancer GWAS and candidate gene meta-analyses reveals limited overlap but similar effect sizes.

Authors:  Christine Q Chang; Ajay Yesupriya; Jessica L Rowell; Camilla B Pimentel; Melinda Clyne; Marta Gwinn; Muin J Khoury; Anja Wulf; Sheri D Schully
Journal:  Eur J Hum Genet       Date:  2013-07-24       Impact factor: 4.246

3.  Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer.

Authors:  Hannah Carter; Rachel Marty; Matan Hofree; Andrew M Gross; James Jensen; Kathleen M Fisch; Xingyu Wu; Christopher DeBoever; Eric L Van Nostrand; Yan Song; Emily Wheeler; Jason F Kreisberg; Scott M Lippman; Gene W Yeo; J Silvio Gutkind; Trey Ideker
Journal:  Cancer Discov       Date:  2017-02-10       Impact factor: 39.397

4.  Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions.

Authors:  Wanqing Liu; Lijun He; Jacqueline Ramírez; Soundararajan Krishnaswamy; Rajani Kanteti; Yi-Ching Wang; Ravi Salgia; Mark J Ratain
Journal:  Cancer Res       Date:  2011-02-03       Impact factor: 12.701

5.  SNP variants at the MAP3K1/SETD9 locus 5q11.2 associate with somatic PIK3CA variants in breast cancers.

Authors:  Roberto Puzone; Ulrich Pfeffer
Journal:  Eur J Hum Genet       Date:  2016-12-28       Impact factor: 4.246

Review 6.  Cancer genome landscapes.

Authors:  Bert Vogelstein; Nickolas Papadopoulos; Victor E Velculescu; Shibin Zhou; Luis A Diaz; Kenneth W Kinzler
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

7.  A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.

Authors:  Outi Kilpivaara; Semanti Mukherjee; Alison M Schram; Martha Wadleigh; Ann Mullally; Benjamin L Ebert; Adam Bass; Sachie Marubayashi; Adriana Heguy; Guillermo Garcia-Manero; Hagop Kantarjian; Kenneth Offit; Richard M Stone; D Gary Gilliland; Robert J Klein; Ross L Levine
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

Review 8.  Integrative eQTL-based analyses reveal the biology of breast cancer risk loci.

Authors:  Qiyuan Li; Ji-Heui Seo; Barbara Stranger; Aaron McKenna; Itsik Pe'er; Thomas Laframboise; Myles Brown; Svitlana Tyekucheva; Matthew L Freedman
Journal:  Cell       Date:  2013-01-31       Impact factor: 41.582

9.  Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies.

Authors:  Francis S Collins; Anna D Barker
Journal:  Sci Am       Date:  2007-03       Impact factor: 2.142

10.  Systematic genetic analysis identifies Cis-eQTL target genes associated with glioblastoma patient survival.

Authors:  Qing-Rong Chen; Ying Hu; Chunhua Yan; Kenneth Buetow; Daoud Meerzaman
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240
  10 in total
  1 in total

Review 1.  Functional germline variants as potential co-oncogenes.

Authors:  Divyansh Agarwal; Christoph Nowak; Nancy R Zhang; Lajos Pusztai; Christos Hatzis
Journal:  NPJ Breast Cancer       Date:  2017-11-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.